Bioporto ASTHOXF 66 Gross Margin % is 92.26% as of Dec. 2025, which is 38% above its 10-year median of 66.71. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Bioporto AS ranks better than 81.96% on this metric.
The historical rank and industry rank for Bioporto AS's Gross Margin % or its related term are showing as below:
THOXF'
s Gross Margin % Range Over the Past 10 Years
Min: 57.49 Med: 66.71 Max: 75.74
Current: 75.44
During the past 13 years, the highestGross Margin % of Bioporto AS was 75.74%. The lowest was 57.49%. And the median was 66.71%.
THOXF's Gross Margin % is ranked better than 81.96% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs THOXF: 75.44
Bioporto AS had a gross margin of 92.26% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bioporto AS was 4.70% per year.
Bioporto AS (OTCPK:THOXF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bioporto AS had a gross margin of 92.26% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bioporto AS Gross Margin % Related Terms
Bioporto AS Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bioporto AS (THOXF) has a Gross Margin % of 92.26% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bioporto AS and its competitors. This is 38% above median its historical median of 66.71. Over the past decade, Bioporto AS's Gross Margin % has ranged from 57.49 to 75.74. According to the industry distribution chart, Bioporto AS ranks #35 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 18%.
Is Bioporto AS's Gross Margin % too high?
Bioporto AS's current Gross Margin % of 92.26% is 38% above median its 10-year median of 66.71. Over the past 10 years, this metric has ranged from a low of 57.49 to a high of 75.74. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. Bioporto AS's value of 92.26% is 82.9% above this industry median. Based on the distribution chart, Bioporto AS ranks #35 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #35 out of 194 companies for Gross Margin %. This places Bioporto AS in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.45. Bioporto AS's value of 92.26% is 82.9% above this benchmark. Historically, Bioporto AS's own Gross Margin % has ranged from 57.49 to 75.74 over the past decade. While the company's 10-year median is 66.71 vs. the industry median of 50.45, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Gross Margin % of 92.26% is 82.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Gross Margin % is 92.26%, which is 38% above median its own 10-year median of 66.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Gross Margin % of 92.26%. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current Gross Margin % is 92.26%, which is 38% above median its 10-year median of 66.71 and 82.9% above the Medical Diagnostics & Research industry median of 50.45. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Gross Margin % is 92.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
Gross Margin %: 92.26% (38% above median its 10-year median of 66.71)
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
Industry Position: 82.9% above the Medical Diagnostics & Research median (#35 of 194)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
